Enoxacin
- Generic Name
- Enoxacin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H17FN4O3
- CAS Number
- 74011-58-8
- Unique Ingredient Identifier
- 325OGW249P
- Background
A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.
- Indication
For the treatment of adults (≥18 years of age) with the following infections caused by susceptible strains of the designated microorganisms: (1) uncomplicated urethral or cervical gonorrhea due to Neisseria gonorrhoeae, (2) uncomplicated urinary tract infections (cystitis) due to Escherichia coli, Staphylococcus epidermidis, or Staphylococcus saprophyticus, and (3) complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus epidermidis, or Enterobacter cloacae.
- Associated Conditions
- -
- Associated Therapies
- -
Enoxacin for Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- McGill University
- Target Recruit Count
- 8
- Registration Number
- NCT04840823
- Locations
- 🇨🇦
Montreal Neurological Institute-Hospital, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.